Adaptive Biotechnologies Corporation — Cash Flow (NASDAQ:ADPT) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Cash from operating activities 149.68 M192.73 M183.94 M156.32 M95.21 M45.99 M 45.99 M Cash from investing activities 117.04 M181.21 M2.9 M129.65 M77.79 M37.95 M 37.95 M Cash from financing activities 293.59 M27.15 M132.26 M2.25 M241 K30.4 M 30.4 M Free cash flow 130.88 M130.98 M167.6 M145.63 M91.55 M43.03 M 43.03 M

Noticias

3 ‘Strong Buy’ Stocks to Buy Now, 2/6/2026, According to Top Analysts - TipRanks.com

Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript

TD Cowen eleva el precio objetivo de Adeptus Biotechnologies a 21 dólares

Adeptus Biotechnologies stock price target raised to $21 by TD Cowen

Thursday’s Insider Activity: Cavco Director Buys as Execs Sell Off

Adaptive Biotechnologies Corporation 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:ADPT) 2026-02-06

BTIG eleva precio objetivo de Adeptus Biotechnologies a $22 por fuerte crecimiento

Adeptus Biotechnologies stock price target raised to $22 by BTIG on strong MRD growth

Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Diapositivas del cuarto trimestre de 2025 de Adaptive Biotechnologies: crecimiento del 55% en ingresos mientras se expande el negocio de EMR

Diapositivas del 4T 2025 de Adaptive Biotechnologies: 55% de crecimiento por expansión MRD

Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Misses Revenue Estimates